Wall Street analysts predict that Heron Therapeutics Inc (NASDAQ:HRTX) will post ($0.85) earnings per share for the current quarter, according to Zacks. Five analysts have provided estimates for Heron Therapeutics’ earnings. The highest EPS estimate is ($0.57) and the lowest is ($1.04). Heron Therapeutics reported earnings per share of ($1.00) during the same quarter last year, which would suggest a positive year over year growth rate of 15%. The company is scheduled to report its next earnings report on Wednesday, May 9th.
On average, analysts expect that Heron Therapeutics will report full year earnings of ($2.56) per share for the current year, with EPS estimates ranging from ($3.95) to ($1.83). For the next fiscal year, analysts expect that the business will report earnings of ($0.77) per share, with EPS estimates ranging from ($1.79) to $0.88. Zacks’ earnings per share averages are a mean average based on a survey of research firms that cover Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.29). Heron Therapeutics had a negative net margin of 641.87% and a negative return on equity of 230.70%. The company had revenue of $10.05 million for the quarter, compared to the consensus estimate of $9.00 million.
A number of analysts recently issued reports on the company. ValuEngine upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. Oppenheimer set a $27.00 price objective on Heron Therapeutics and gave the company a “buy” rating in a research note on Thursday, March 1st. Noble Financial reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Friday, March 2nd. Needham & Company LLC reiterated a “buy” rating and set a $30.00 price objective (up from $28.00) on shares of Heron Therapeutics in a research note on Thursday, March 1st. Finally, Cantor Fitzgerald set a $31.00 price objective on Heron Therapeutics and gave the company a “buy” rating in a research note on Tuesday, February 27th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $30.08.
Heron Therapeutics (NASDAQ HRTX) traded down $0.30 during trading hours on Friday, hitting $21.90. The company had a trading volume of 851,167 shares, compared to its average volume of 1,026,686. Heron Therapeutics has a 12 month low of $12.70 and a 12 month high of $25.35. The company has a market cap of $1,554.79, a price-to-earnings ratio of -6.04 and a beta of 1.87.
In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of the company’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $20.00, for a total value of $151,680.00. Following the transaction, the vice president now directly owns 7,584 shares in the company, valued at approximately $151,680. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 19.93% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in HRTX. Ellington Management Group LLC bought a new position in Heron Therapeutics in the 4th quarter worth about $195,000. Pinnacle Associates Ltd. bought a new position in shares of Heron Therapeutics during the 4th quarter valued at about $201,000. Trexquant Investment LP bought a new position in shares of Heron Therapeutics during the 3rd quarter valued at about $206,000. Jefferies Group LLC bought a new position in shares of Heron Therapeutics during the 4th quarter valued at about $214,000. Finally, Jane Street Group LLC bought a new position in shares of Heron Therapeutics during the 3rd quarter valued at about $223,000.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.